|
1
|
Haybittle JL, Blamey RW, Elston CW, et al:
A prognostic index in primary breast cancer. Br J Cancer.
45:361–366. 1982.
|
|
2
|
Blamey RW, Ellis IO, Pinder SE, et al:
Survival of invasive breast cancer according to the Nottingham
Prognostic Index in cases diagnosed in 1990–1999. Eur J Cancer.
43:1548–1555. 2007.
|
|
3
|
Ravdin PM, Siminoff LA, Davis GJ, et al:
Computer program to assist in making decisions about adjuvant
therapy for women with early breast cancer. J Clin Oncol.
19:980–991. 2001.
|
|
4
|
Olivotto IA, Bajdik CD, Ravdin PM, et al:
Population-based validation of the prognostic model ADJUVANT! for
early breast cancer. J Clin Oncol. 23:2716–2725. 2005.
|
|
5
|
Mook S, Schmidt MK, Rutgers EJ, et al:
Calibration and discriminatory accuracy of prognosis calculation
for breast cancer with the online Adjuvant! program: a
hospital-based retrospective cohort study. Lancet Oncol.
10:1070–1076. 2009.
|
|
6
|
Campbell HE, Taylor MA, Harris AL and Gray
AM: An investigation into the performance of the Adjuvant! Online
prognostic programme in early breast cancer for a cohort of
patients in the United Kingdom. Br J Cancer. 101:1074–1084.
2009.
|
|
7
|
Wishart GC, Azzato EM, Greenberg DC, et
al: PREDICT: a new UK prognostic model that PREDICTs survival
following surgery for invasive breast cancer. Breast Cancer Res.
12:R12010.
|
|
8
|
Wishart GC, Bajdik CD, Azzato EM, et al: A
population-based validation of the prognostic model PREDICT for
early breast cancer. Eur J Surg Oncol. 37:411–417. 2011.
|
|
9
|
Mook S, Van’t Veer LJ, Rutgers EJ, et al:
Independent prognostic value of screen detection in invasive breast
cancer. J Natl Cancer Inst. 103:585–597. 2011.
|
|
10
|
Romond EH, Perez EA, Bryant J, et al:
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive
breast cancer. N Engl J Med. 353:1673–1684. 2005.
|
|
11
|
Slamon D, Eiermann W, Robert N, et al:
Breast Cancer International Research Group: Adjuvant trastuzumab in
HER2-positive breast cancer. N Engl J Med. 365:1273–1283. 2011.
|
|
12
|
Joensuu H, Bono P, Kataja V, et al:
Fluorouracil, epirubicin, and cyclophosphamide with either
docetaxel or vinorelbine, with or without trastuzumab, as adjuvant
treatments of breast cancer: final results of the FinHer Trial. J
Clin Oncol. 27:5685–5692. 2009.
|
|
13
|
Smith I, Procter M, Gelber RD, et al:
2-year follow-up of trastuzumab after adjuvant chemotherapy in
HER2-positive breast cancer: a randomised controlled trial. Lancet.
369:29–36. 2007.
|
|
14
|
Wishart GC, Bajdik CD, Dicks E, et al:
PREDICT Plus: development and validation of a prognostic model for
early breast cancer that includes HER2. Br J Cancer. 107:800–807.
2012.
|
|
15
|
Rakha EA, Soria D, Green AR, et al:
Nottingham Prognostic Index Plus (NPI+): a modern clinical decision
making tool in breast cancer. Br J Cancer. 110:1688–1697. 2014.
|
|
16
|
No authors listed. Polychemotherapy for
early breast cancer: an overview of the randomised trials. Early
Breast Cancer Trialists’ Collaborative Group. Lancet. 352:930–942.
1998.
|
|
17
|
Baselga J, Perez EA, Pienkowski T and Bell
R: Adjuvant trastuzumab: a milestone in the treatment of
HER-2-positive early breast cancer. Oncologist. 11(Suppl 1): 4–12.
2006.
|
|
18
|
Urruticoechea A, Smith IE and Dowsett M:
Proliferation marker Ki-67 in early breast cancer. J Clin Oncol.
23:7212–7220. 2005.
|
|
19
|
Ohzawa H, Sakatani T, Niki T, Yasuda Y and
Hozumi Y: Pathological responses and survival of patients with
human epidermal growth factor receptor 2-positive breast cancer who
received neoadjuvant chemotherapy including trastuzumab. Breast
Cancer. Oct 30–2012.(Epub ahead of print).
|
|
20
|
von Minckwitz G, Loibl S and Untch M: What
is the current standard of care for anti-HER2 neoadjuvant therapy
in breast cancer? Oncology (Williston Park). 26:20–26. 2012.
|
|
21
|
Second All Cancer Breast Report. 2007, NHS
breast screening programme publication. http://www.cancerscreening.nhs.uk/breastscreen/second-all-breast-cancer-report.pdf.
Accessed January 2013
|
|
22
|
An audit of screen detected breast cancers
for the year of screening April 2010 to March 2011. NHSBSP &
Association of Breast Surgery; May. 2012, http://www.cancerscreening.nhs.uk/breastscreen/publications/baso2010-2011.pdf.
Accessed January 2013
|
|
23
|
Wishart GC, Greenberg DC, Chou P, Brown
CH, Duffy S and Purushotham AD: Treatment and survival in breast
cancer in the Eastern Region of England. Ann Oncol. 21:291–296.
2010.
|
|
24
|
Ali AM, Greenberg D, Wishart GC and
Pharoah P: Patient and tumour characteristics, management, and
age-specific survival in women with breast cancer in the East of
England. Br J Cancer. 104:564–570. 2011.
|
